公开(公告)号：US20220241277A1

公开(公告)日：2022-08-04

申请号：US17714996

申请日：2022-04-06

Applicant: Novartis AG ,  The General Hospital Corporation

Inventor： Leila DARDAEI ALGHALANDIS ,  Jeffrey Adam ENGELMAN ,  Huaixiang HAO ,  Matthew J. LAMARCHE ,  Fang LI ,  Hui-Qin WANG

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising an ALK inhibitor, in free form or a pharmaceutically acceptable salt thereof, and a SHP2 inhibitor, in free form or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20210363254A1

公开(公告)日：2021-11-25

申请号：US16981828

申请日：2019-03-18

Applicant: Novartis AG

Inventor： Stephane FERRETTI ,  Nelson GUERREIRO ,  Ensar HALILOVIC ,  Sebastien JEAY ,  Astrid JULLION ,  Jinsheng LIANG ,  Christophe MEILLE ,  Hui-Qin WANG ,  Jens WUERTHNER

IPC: C07K16/28 ,  A61P35/00 ,  C07D487/04

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) a HDM2-p53 interaction inhibitor, said combination for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease, a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination; said proliferative disease being a TP53 wildtype tumor, in particular TP53 wildtype renal cell carcinoma (RCC) or TP53 wildtype colorectal cancer (CRC).

公开(公告)号：US20220280523A1

公开(公告)日：2022-09-08

申请号：US17644491

申请日：2021-12-15

Applicant: Novartis AG

Inventor： Giordano CAPONIGRO ,  Xizhong HUANG ,  Joseph LEHAR ,  Hui-Qin WANG

IPC: A61K31/53 ,  A61K45/06 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377

Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

公开(公告)号：US20190134033A1

公开(公告)日：2019-05-09

申请号：US16180078

申请日：2018-11-05

Applicant: Novartis AG

Inventor： Fang LI ,  Hui-Qin WANG ,  Ensar HALILOVIC ,  Jinsheng LIANG

IPC: A61K31/506 ,  A61K31/496 ,  A61K31/435 ,  A61K45/06 ,  A61K31/4025 ,  A61K31/404

Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.